Objective: To study the effects of symbicort turbuhaler combined with tiotropium bromide on serum PCT, TIMP-1, MMP-9, IFN-γ, arterial blood gases and pulmonary function in patients with AECOPD. Methods A total of 90 ...Objective: To study the effects of symbicort turbuhaler combined with tiotropium bromide on serum PCT, TIMP-1, MMP-9, IFN-γ, arterial blood gases and pulmonary function in patients with AECOPD. Methods A total of 90 patients in our hospital with AECOPD during January 2014 to January 2017 were divided into the control group (n=45) and the treatment group (n=45) randomly. The control group was treated with tiotropium bromide;the treatment group was treated with symbicort turbuhaler combined with tiotropium bromide. The two groups were treated for 14 d. That was compared of the serum PCT, TIMP-1, MMP-9, IFN-γ, PaO2, SaO2, PaCO2, MPAP, PASP and PADP of the two groups before and after treatment. Results The serum PCT, TIMP-1, MMP-9, IFN-γ, PaO2, SaO2, PaCO2, MPAP, PASP and PADP of the two groups before treatment have no significantly differences. The serum PCT, TIMP-1, MMP-9 and IFN-γ levels of the two groups after treatment were significantly lower than before treatment. The serum PCT, TIMP-1, MMP-9 and IFN-γ levels of the treatment group after treatment were significantly lower than the control group. The PaO2, SaO2 of the two groups after treatment were significantly higher than before treatment, the PaCO2, MPAP, PASP and PADP of the two groups after treatment were significantly lower than before treatment. The PaO2, SaO2, PaCO2, MPAP, PASP and PADP of the treatment group after treatment were significantly better than the control group. Conclusion Symbicort turbuhaler combined with tiotropium bromide can reduce the serum PCT, TIMP-1, MMP-9, IFN-γlevels and the pulmonary arterial hypertension, improve the lung tissue oxygen supply and the cardiopulmonary function, and it was worthy clinical application.展开更多
AstraZeneca公司的复方哮喘治、疗药物Symbicort（Ⅰ）（budesonide plus formoterol，布地奈德加福莫特罗）（Ⅰ）经过长期的等待后，终于在美国上市，用于12岁及12岁以上患者的长期维持性治疗。现在（Ⅰ）与GlaxoSmithKline公司的类...AstraZeneca公司的复方哮喘治、疗药物Symbicort（Ⅰ）（budesonide plus formoterol，布地奈德加福莫特罗）（Ⅰ）经过长期的等待后，终于在美国上市，用于12岁及12岁以上患者的长期维持性治疗。现在（Ⅰ）与GlaxoSmithKline公司的类似产品Advair（salmeterol plus fluticasone，沙美特罗加氟替卡松）并驾齐驱。这两种复方产品都含有一种长效β2激动剂和一种吸入性皮质醇。展开更多
文摘Objective: To study the effects of symbicort turbuhaler combined with tiotropium bromide on serum PCT, TIMP-1, MMP-9, IFN-γ, arterial blood gases and pulmonary function in patients with AECOPD. Methods A total of 90 patients in our hospital with AECOPD during January 2014 to January 2017 were divided into the control group (n=45) and the treatment group (n=45) randomly. The control group was treated with tiotropium bromide;the treatment group was treated with symbicort turbuhaler combined with tiotropium bromide. The two groups were treated for 14 d. That was compared of the serum PCT, TIMP-1, MMP-9, IFN-γ, PaO2, SaO2, PaCO2, MPAP, PASP and PADP of the two groups before and after treatment. Results The serum PCT, TIMP-1, MMP-9, IFN-γ, PaO2, SaO2, PaCO2, MPAP, PASP and PADP of the two groups before treatment have no significantly differences. The serum PCT, TIMP-1, MMP-9 and IFN-γ levels of the two groups after treatment were significantly lower than before treatment. The serum PCT, TIMP-1, MMP-9 and IFN-γ levels of the treatment group after treatment were significantly lower than the control group. The PaO2, SaO2 of the two groups after treatment were significantly higher than before treatment, the PaCO2, MPAP, PASP and PADP of the two groups after treatment were significantly lower than before treatment. The PaO2, SaO2, PaCO2, MPAP, PASP and PADP of the treatment group after treatment were significantly better than the control group. Conclusion Symbicort turbuhaler combined with tiotropium bromide can reduce the serum PCT, TIMP-1, MMP-9, IFN-γlevels and the pulmonary arterial hypertension, improve the lung tissue oxygen supply and the cardiopulmonary function, and it was worthy clinical application.
文摘AstraZeneca公司的复方哮喘治、疗药物Symbicort（Ⅰ）（budesonide plus formoterol，布地奈德加福莫特罗）（Ⅰ）经过长期的等待后，终于在美国上市，用于12岁及12岁以上患者的长期维持性治疗。现在（Ⅰ）与GlaxoSmithKline公司的类似产品Advair（salmeterol plus fluticasone，沙美特罗加氟替卡松）并驾齐驱。这两种复方产品都含有一种长效β2激动剂和一种吸入性皮质醇。
